NCT01081730View on ClinicalTrials.gov

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

CompletedOBSERVATIONAL
Enrollment

2,040

Participants

Timeline

Start Date

February 9, 2010

Primary Completion Date

September 29, 2017

Study Completion Date

September 29, 2017

Conditions
Psoriasis
Interventions
BIOLOGICAL

anti-TNF biologics

as prescribed

OTHER

general population

non-treated cohort

BIOLOGICAL

non-anti-TNF biologics

as prescribed

BIOLOGICAL

ustekinumab

as prescribed

DRUG

systemic non-biological treatments

as prescribed

Sponsors
All Listed Sponsors
lead

Janssen Biotech, Inc.

INDUSTRY

NCT01081730 - Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database | Biotech Hunter | Biotech Hunter